Gilead Sciences, Inc.

NASDAQ:GILD  
61.69
-1.38 (-2.19%)
Products, Regulatory

Gilead Announces First Global Regulatory Approval Of Sunlenca (Lenacapavir), The Only Twice-Yearly HIV Treatment Option

Published: 08/22/2022 05:13 GMT
Gilead Sciences, Inc. (GILD) - Gilead Announces First Global Regulatory Approval of Sunlenca® (lenacapavir), the Only Twice-yearly Hiv Treatment Option.
Says FDA Has Assigned a Prescription Drug User Fee Act (pdufa) Action Date of December 27, 2022.
Says Marketing Authorization Application (maa) for Lenacapavir is Supported by Data From Phase 2/3 Capella Study.